Role of the Nucleus Raphe Magnus in Antinociception Produced by ABT-594: Immediate Early Gene Responses Possibly Linked to Neuronal Nicotinic Acetylcholine Receptors on Serotonergic Neurons


Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064-3500

Recently, a novel cholinergic channel modulator, (R)-5-(2-azetidinymethoxy)-2-chloropyridine (ABT-594), was shown to produce potent analgesia in a variety of rodent pain models when administered either systemically or centrally into the nucleus raphe magnus (NRM). The purpose of the present study was to investigate the possible supraspinal contribution of ABT-594 by assessing its ability to induce expression of the immediate early gene c-fos, a biochemical marker of neuronal activation, in the NRM of rats. Putative serotonergic neurons in the NRM, a medullary nucleus proposed to be involved in descending antinociceptive pathways, were identified immunohistochemically using a monoclonal antibody (mAb) against tryptophan hydroxylase. ABT-594 (0.03–0.3 μmol/kg, i.p.) produced a dose-dependent induction of Fos protein that was blocked by the central nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (5 μmol/kg, i.p.) but not by the peripheral nAChR antagonist hexamethonium (15 μmol/kg, i.p.). Immunohistological studies using mAb 299 revealed the expression of α4-containing nAChRs in the NRM. The α4 immunostaining was dramatically reduced by pretreating (30 d) animals with the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT), which was previously shown to substantially attenuate the antinociceptive actions of ABT-594. In a double immunohistochemical labeling experiment, coexpression of the serotonin marker tryptophan hydroxylase and the α4 nAChR subunit in NRM neurons was observed. These results suggest that the analgesic mechanism of ABT-594 may in part involve the activation of the NRM, a site where α4-containing nAChRs are expressed by serotonergic neurons.

Key words: ABT-594; nucleus raphe magnus; c-fos expression; nicotinic antagonism; serotonin; α4-containing nicotinic acetylcholine receptor; antinociception

Antinociception produced by nicotine was first reported 60 years ago (Davis et al., 1932), yet the use of nicotinic acetylcholine receptor (nAChR) agonists as viable analgesics has received limited consideration. However, the discovery of epibatidine, a potent nAChR agonist with analgesic properties (for review, see Sullivan and Bannon, 1996) and the cloning of neuronal nAChR subunits (Sargent, 1993; McGehee and Role, 1995) have provided a stronger basis for investigation of analgesic nicotinides that act more selectively in the CNS. Indeed, the novel nAChR agonist (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594) was recently reported to produce antinociception equal in efficacy to morphine in a variety of rodent pain models after systemic and central administration (Bannon et al., 1998).

The nucleus raphe magnus (NRM) is a serotonergic nucleus located in the rostral ventromedial medulla of the brainstem. Axons of the NRM project to the spinal cord (Bowker et al., 1982), terminating primarily in the dorsal horn (Jones and Light, 1990). Brainstem nuclei that project to the dorsal horn of the spinal cord can function to inhibit afferent nociceptive transmission (Basbaum and Fields, 1979; Willis, 1988; Sandkühler, 1996).

Activation of these descending antinociceptive pathways may be triggered by physiological stimuli (Millan et al., 1980) as well as by pharmacological agents (Gogas et al., 1991). Antinociception involving the NRM has been studied after either electrical stimulation or direct administration of pharmacological agents (Proudfit and Anderson, 1975; Oleson et al., 1978; Brodie and Proudfit, 1986).

Iwamoto (1991) reported that nicotine injected directly into the NRM produced antinociception in rat models of thermal pain. Similarly, we demonstrated that an intra-NRM injection of ABT-594 produced antinociception in a thermal model of acute and a chronic model of persistent pain (Curzon et al., 1997; Bannon et al., 1998). Mapping studies in the rat have revealed the expression of different nAChR subunits in various brainstem regions at the RNA (Wada et al., 1989) and protein (Swanson et al., 1987) levels, supporting an nAChR-mediated mechanism of antinociception involving a supraspinal site of action. However, to date there are no reports specifically identifying nAChR expression in the NRM.

The purpose of the present study was to further investigate the possible contribution of the NRM to antinociception produced by systemic ABT-594. Expression of the immediate early gene c-fos is triggered by a variety of depolarizing events (Morgan et al., 1987; Sagar et al., 1988; Morgan and Curran, 1991), including nAChR activation (Greenberg et al., 1986). We previously demonstrated that an antinociceptive dose of ABT-594 given sistem-
ically produced an increase in c-fos expression in the NRM of rats (Bannon et al., 1998). Here, further studies were conducted to determine the ability of ABT-594 to induce the expression of Fos protein in the NRM as an in situ marker of nAChR activation. Effects of nAChR antagonism on ABT-594-induced c-fos expression were also assessed. In addition, the expression of the α4 subunit of the nAChR in the NRM was immunohistochemically evaluated. To specifically test the possibility that α4-containing nAChRs are expressed by serotonin-containing neurons, we also examined the effects of a local serotonergic lesion on α4 expression in the NRM and assessed coexpression by double immunohistochemical labeling.

MATERIALS AND METHODS

Animals and experimental treatments. Male Sprague Dawley rats (Charles River Laboratories, Portage, MI) weighing 350–400 g were used. The animals were group-housed in an American Association for the Accreditation of Laboratory Animal Care-approved facility at Abbott Laboratories (Abbott Park, IL) in a temperature-regulated environment with lights on between 7:00 A.M. and 8:00 P.M. All experimental procedures involving animals were conducted under protocols approved by Abbott's Institutional Animal Care and Use Committee.

Rats received a single intraperitoneal injection of either saline (1 ml/kg) or ABT-594 (0.03, 0.1, or 0.3 μmol/kg) or, in other studies, were pretreated with either the nAChR antagonists hexamethonium (15 μmol/kg, i.p.) or mecamylamine (5 μmol/kg, i.p.) followed 15 min later by ABT-594 (0.3 μmol/kg, i.p). Two hours after drug treatment the animals were deeply anesthetized with pentobarbital and perfused through the aorta with buffered saline (3 min, 25 ml/min) followed by 10% formalin (12 min, 30 ml/min). The brains were removed and post-fixed in either 10% formalin or 20% sucrose PBS for 12–24 hr before immunohistochemical assessment.

Rats were anesthetized intraperitoneally with 55 mg/kg sodium pentobarbital and placed in a David Kopf student stereotaxic instrument (Tujunga, CA) with the skull on an even horizontal plane. Coordinates for intra-NRM injections from intra-aural zero were anteroposterior, −2.5 mm; mediolateral, 0.0 mm; and dorsoventral −0.5 mm. Rats were then injected with either PBS or the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT; 3.75 nmol in 0.3 μl over 60 sec) using a 31 gauge injector. Thirty days after an intra-NRM injection of 5,7-DHT (or PBS), the animals were anesthetized and perfused, as described above. The ability of an intra-NRM injection of 5,7-DHT to produce a serotonergic lesion was determined by assessing tryptophan hydroxylase immunostaining throughout the NRM.

Compounds. ABT-594 was synthesized (Holladay et al., 1997) at Abbott Laboratories. Mecamylamine hydrochloride, hexamethonium hydrochloride, and 5,7-dihydroxytryptamine creatine sulfate were obtained from Sigma (St. Louis, MO).

Immunohistochemistry of paraffin sections. After post-fixation in 10% formalin, brains from saline-treated animals were processed and embedded in paraffin, sectioned (6 μm), and mounted on aminosilane-coated glass slides (Newcomer Supply). Specifically, coronal sections from the brainstem that contained the NRM (~9.3 mm to ~11.0 mm from bregma; Paxinos and Watson, 1997) were mounted. The immunohistochemical procedure used consisted of a three-step avidin–biotin complex (ABC)–peroxidase technique. Sections were first deparaffinized through a xylene and graded alcohol series, followed by a 20 min incubation in 3% H2O2 in methanol to block endogenous peroxidase activity. The same sections were then incubated with blocking serum. The sections were then incubated with appropriate primary antibodies for 60 min, washed in PBS, and then incubated with biotinylated secondary antibodies, followed by a wash and incubation in ABC reagent. The sections were then washed in PBS and incubated in a diaminobenzidine substrate solution (diaminobenzidine) and counterstained with hematoxylin. Sections were examined and photographed under a light microscope (Leica, DMRB) and compared with the previous fluorescence micrographs for double labeling.

Figure 1. Immunohistochemical identification of the nucleus raphe magnus (NRM). The rat NRM is located (open square) in the rostral ventromedial medulla and is centered just above the pyramidal tract at the base of the brainstem (A) (adapted from Paxinos and Watson, 1997). Serotonergic neurons of the NRM (B) were immunohistochemically identified using an mAb against tryptophan hydroxylase in a saline-treated rat. Scale bar, 100 μm.
hr with a biotinylated secondary anti-sheep Ab solution (1:200). Finally, sections were washed in PBS, incubated with ABC reagent (Vector Laboratories), and then developed in a peroxidase substrate solution. The sections were mounted, coverslipped, examined, and photographed with a light microscope (Leica, DMRB). Fos-like immunoreactivity (FLI) was quantified using an image analysis system (Leica, Quantimet 500) that identified and counted immunostained neurons according to a gray level that was empirically determined before analysis.

Statistics. Data were analyzed using ANOVA followed by Fisher’s protected least significant difference (PLSD) post hoc test. Statistical analyses on data were performed using StatView (Abacus Concepts, Calabasas, CA).

RESULTS
Neurochemical–immunohistochemical identification of the NRM
Studies were conducted to immunohistologically identify the serotonin-containing neurons of the NRM using an antibody against the rate-limiting enzyme of serotonin synthesis, tryptophan hydroxylase. Positive immunostaining was observed centered above the left and right pyramidal tracts in the medial ventral medulla, the location of the NRM (Fig. 1). A similar pattern of staining in the NRM was also observed using a polyclonal Ab against serotonin that was prevented by preincubation of the primary Ab with 20 μg/ml serotonin (data not shown).

ABT-594-induced Fos expression in the NRM
The ability of ABT-594 to induce the expression of Fos protein in the NRM was used as an in situ measure of neuronal activation. Two hours after systemic administration of ABT-594 (0.03, 0.1, and 0.3 μmol/kg, i.p.), an increase in Fos immunostaining was observed in the NRM (Fig. 2). Fos-like immunoreactivity was quantitated using a Quanitmet 500+ image analysis system. ABT-594 produced a dose-dependent induction of FLI in the NRM ($F_{(3,20)} = 7.336; p = 0.0017$), as illustrated in Figure 3.
At the higher 0.3 \( \text{mol/kg} \) dose, ABT-594 produced a fourfold increase in Fos expression compared with saline-treated controls (\( p, 0.01 \)).

The effects of \( \alpha \text{nAChR} \) antagonist on ABT-594-induced c-fos expression are summarized in Figure 4. In these experiments, ABT-594 (0.3 \( \text{mol/kg}, \text{i.p.}) \) produced a significant increase in FLI (\( p, 0.05 \)) that was blocked by pretreatment with the \( \alpha \text{nAChR} \) antagonist mecamylamine (15 \( \text{mol/kg}, \text{i.p.}) \) 15 min before ABT-594 did not prevent ABT-594-induced Fos expression in the NRM of rats (\( n = 4–6 \text{ per group} \) 2 hr later (A). Administration of the peripheral \( \alpha \text{nAChR} \) antagonist hexamethonium (15 \( \text{mol/kg}, \text{i.p.}) \) 15 min before ABT-594 (0.3 \( \text{mol/kg}, \text{i.p.}) \) did not prevent ABT-594-induced Fos expression in the NRM of rats (\( n = 4–6 \text{ per group} \) 2 hr later (B). FLI is expressed as the percent of saline control FLI mean ± SEM (*\( p < 0.05 \) compared with saline-treated rats; +\( p < 0.05 \) as compared with ABT-594-treated rats; PLSD post hoc test).

At the higher 0.3 \( \text{mol/kg} \) dose, ABT-594 produced a fourfold increase in Fos expression compared with saline-treated controls (\( p < 0.01 \)).

The effects of \( \alpha \text{nAChR} \) antagonist on ABT-594-induced c-fos expression are summarized in Figure 4. In these experiments, ABT-594 (0.3 \( \text{mol/kg}, \text{i.p.}) \) produced a significant increase in FLI (\( p < 0.05 \)) that was blocked by pretreatment with the \( \alpha \text{nAChR} \) antagonist mecamylamine (5 \( \text{mol/kg}, \text{i.p.}) \). In contrast, pretreatment with the peripheral \( \alpha \text{nAChR} \) antagonist hexamethonium (15 \( \text{mol/kg}, \text{i.p.}) \) did not prevent the expression of Fos produced by ABT-594 (0.3 \( \text{mol/kg} \)).

**nAChR expression in the NRM**

Immunohistochemical analysis of \( \alpha 4 \)-containing \( \alpha \text{nAChRs} \) in the NRM is summarized in Figure 5. Expression of the \( \alpha 4 \) \( \alpha \text{nAChR} \) was observed in the NRM using mAb 299. At higher magnification, it was evident that the immunostaining was greatest in the soma of the neurons, with the exception of the nucleus, but positive staining was also present in the neuropil. Using a polyclonal Ab raised against the C terminus of the \( \alpha 4 \) subunit, a similar pattern of staining compared with mAb 299 was observed and was prevented with preincubation of the peptide (20 \( \mu \text{g/ml} \)) to raise the Ab (data not shown). Alternatively, there were neurons in the NRM that did not show expression of the \( \alpha 4 \) subunit.

**Intra-NRM 5,7-DHT and \( \alpha \text{nAChR} \) expression**

To examine the effects of a serotonergic NRM lesion on the expression of \( \alpha 4 \)-containing neurons in the NRM, rats received a single intra-NRM injection of 5,7-DHT, a serotonin neurotoxin. Immunohistochemical assessment of the expression of both the serotonin marker tryptophan hydroxylase and the \( \alpha 4 \) subunit of the \( \alpha \text{nAChR} \) was performed 30 d after 5,7-DHT (or PBS) treatment (Fig. 6). A similar pattern of immunostaining with regard to size and number of positive cells in the NRM was observed in a saline-treated rat, using antibodies against tryptophan hydroxylase (Fig. 6A) and the \( \alpha \text{nAChR} \) \( \alpha 4 \) subunit (Fig. 6C). Intra-NRM administration of 5,7-DHT (3.7 nmol) almost completely reduced both tryptophan hydroxylase (Fig. 6B) and \( \alpha 4 \) (Fig. 6D) immunostaining, compared with the saline-treated control rat. However, staining using an antibody against the neurofilament protein NF-200, a neuronal marker, was observed in the NRM of both the PBS and 5,7-DHT-treated rats (data not shown).
Double immunohistochemical labeling of tryptophan hydroxylase and α4

To provide direct proof that α4-containing nAChRs are located on serotonergic neurons in the NRM, double immunohistochemical labeling of tryptophan hydroxylase and α4 was conducted. There was almost a complete overlap of immunostaining for tryptophan hydroxylase (Fig. 7A) compared with α4 (Fig. 7B) in neurons of the NRM. For control experiments (data not shown), the primary Ab against α4 during the second incubation was omitted; no α4 immunoreactivity was observed in these sections. Furthermore, reversing the order of the primary Ab incubations and replacing the anti-tryptophan hydroxylase with a polyclonal Ab against serotonin produced the same type of overlapping pattern of coexpression.

DISCUSSION

We previously demonstrated that intra-NRM administration of ABT-594 produced antinociception in models of acute and persistent pain (Curzon et al., 1997; Bannon et al., 1998). Results of this study further support a role for the NRM as one potential site of action for the antinociception produced by ABT-594. Systemic administration of ABT-594 produced a dose-dependent induction of Fos expression in the NRM that was blocked by systemic mecamylamine, but not hexamethonium. Immunohistochemical evaluation of the NRM revealed the presence of the nAChR α4 subunit, consistent with the possibility that ABT-594-induced c-fos expression may be attributable to the direct activation of an α4-containing nAChR within the NRM. Finally, neurons in the NRM expressing α4 appear to be serotonergic, as evidenced by the loss of α4 expression after intra-NRM administration of the serotonergic neurotoxin 5,7-DHT and, moreover, by the coexpression of tryptophan hydroxylase and α4 revealed by double-labeling experiments.

Induction of the immediate early gene c-fos can be triggered by various stimuli that produce depolarization (Morgan et al., 1987; Sagar et al., 1988; Morgan and Curran, 1991), including the agonist–receptor interaction resulting in the opening of a cation channel, as seen with activation of the nAChR (Greenberg et al., 1986). In this regard, drug-induced expression of c-fos has been used to identify neuronal activation in given brain nuclei (Sagar et al., 1988), thereby revealing potential sites of drug action. The ability of ABT-594 to produce a dose-dependent induction of c-fos expression in the NRM, as observed in these studies, suggests that the NRM may indeed be involved in antinociception produced by systemic administration of ABT-594. Furthermore, antagonism of ABT-594-induced NRM Fos by mecamylamine, but not hexamethonium, suggests that activation of the NRM, whether direct or indirect, requires activation of central nAChRs.

The in situ mapping strategy involving drug-induced Fos expression has been used with systemic administration of (-)-nicotine. Ren and Sagar (1992) reported high levels of Fos immunostaining in the central visual pathways, including the superficial superior colliculus and the medial terminal nucleus as well as the interpeduncular nucleus, after a 60 min intravenous infusion of nicotine in rat. However, in areas known to contain high levels of nicotine-binding sites, such as the medial habenula, thalamus, substantia nigra, and ventral tegmental area (Clarke et al., 1985), nicotine-induced Fos expression was not observed. Moreover, they did not report c-fos induction in the NRM, as
seen in the present study with ABT-594. This may suggest that ABT-594 activates nAChRs differentially from nicotine. Similarly, other studies demonstrating expression of Fos after systemic nicotine administration (Salminen et al., 1996; Pich et al., 1997) do not report activation of the NRM.

Despite the lack of reports that nicotine induces Fos expression in the NRM, (−)-nicotine injected into the NRM has been shown to produce antinociception in the rat hot-plate and tail-flick models of thermal pain (Iwamoto, 1991). We have shown that intra-NRM injection of ABT-594 in rats, consistent with studies using nicotine, produces antinociception in the hot-box test of thermal pain and the formalin test of persistent pain (Curzon et al., 1997). In these studies, systemic mecamylamine pretreatment or intra-NRM coinjection with mecamylamine blocked the antinociceptive effects of ABT-594 injected into the NRM, supporting an nAChR-dependent mechanism in the NRM. In contrast, intra-NRM administration of mecamylamine did not block antinociception produced by systemic injection of ABT-594. This result may suggest that nicotinic activation of the NRM is not required for antinociception produced by systemic ABT-594. However, other sites of action, in addition to the NRM, may be important in mediating the effects of systemic ABT-594 antinociception. In other studies from our laboratory, systemic injection of ABT-594 was shown to also increase Fos expression in the locus coeruleus (Bitner et al., 1997), a brainstem nucleus known to be involved in descending antinociceptive pathways (Yaksh, 1985). Another possible explanation for a lack of antagonism with intra-NRM mecamylamine could lie in the methodology of the experiment itself. The 0.3 μl intra-NRM injection volume of mecamylamine used in the above experiment may not have been sufficient to antagonize all of the nAChRs throughout the entire NRM that would be activated by systemically administered ABT-594.

To examine the possibility that ABT-594 interacts directly with nAChRs in the NRM, immunohistochemical studies were conducted to determine whether the α4 nAChR subunit was expressed in the NRM. It has been suggested that the α4β2 subtype comprises at least 90% of neuronal nAChRs in brain (Flores et al., 1992; Lindstrom et al., 1995). Consistent with Fos mapping, studies using either radioligand autoradiography (Clarke et al., 1985), immunohistochemistry (Swanson et al., 1987), or in situ hybridization (Wada et al., 1989) have identified nAChRs in various brainstem nuclei, including the superior colliculus, the ventral tegmental area, and the interpeduncular nucleus. However, there have been no reports that specifically cite the presence or confirm the expression of nAChR-containing neurons in the NRM, as seen in the present study, and thus these data represent a novel finding.

To neurochemically characterize the type of neuron that may express α4, we assessed the effects of a serotonergic lesion on α4 immunostaining in the NRM. Intra-NRM injection of 5,7-DHT reduced the immunostaining of the rate-limiting enzyme of serotonin biosynthesis tryptophan hydroxylase as well as α4 immunostaining, indicating that serotonergic neurons in the NRM may express α4-containing nAChRs. This was directly confirmed by double-labeling experiments demonstrating that neurons in the NRM coexpress tryptophan hydroxylase and α4 protein.

Because of their descending projections to the dorsal horn of the spinal cord (Bowker et al., 1982), nAChR activation of serotonergic neurons in the NRM by ABT-594 may inhibit afferent nociceptive transmission at the level of the dorsal horn. In support of this proposed mechanism, the antinociceptive effect of systemically administered ABT-594 in a thermal model of pain was reduced by 62% in 5,7-DHT-treated rats, and ABT-594 injected directly into the NRM produced antinociception (Curzon et al., 1997). Similarly, others have demonstrated that either electrical stimulation (Oleson et al., 1978; Brodie and Proudfit, 1986) or pharmacological activation (Proudfit and Anderson, 1975; Iwamoto, 1991) of the NRM can produce antinociception in rats. Antinociception produced by intra-NRM injections of the nicotinic agonist N-methylcarbachol was shown to be blocked by intrathecal administration of the serotonin receptor antagonists LY53857 (5-HT1c/2) and S-(-)-zacopride (5-HT3) (Iwamoto and Marion, 1993), again supporting the possibility that nAChR agonists can stimulate serotonergic neurons in the NRM that descend to the spinal cord to bring about antinociception.

In conclusion, data from the present study provide further evidence consistent with the possibility that the antinociceptive action of the novel nAChR agonist ABT-594 may in part be mediated by activation of the NRM. Moreover, the involvement of the NRM in ABT-594 antinociception may be attributable to the activation of an α4-containing nAChR located on serotonergic neurons. However, it should be emphasized that the NRM

**Figure 7.** Photomicrographs of double labeling of tryptophan hydroxylase and the α4 nAChR subunit in the NRM. Using a fluorescein-conjugated secondary Ab, tryptophan hydroxylase immunostaining (A) shows almost complete overlap compared with the DAB chromogen in α4-containing neurons (B) in the NRM of a saline-treated rat. Double-labeled neurons are indicated by arrows. Scale bar, 100 μm.
may be only one of several nuclei that represent potential sites of antinociceptive action produced by ABT-594, and other subunit-containing nAChRs besides, or in addition to, α4 may be involved. Similar studies, as reported here, involving ABT-594-induced activation of other CNS nuclei as well as the mapping of additional nAChR subunits are ongoing.

REFERENCES


